Home Healthcare Pharmaceuticals Anti-obesity Drugs Market

Anti-obesity Drugs Market Size, Share & Trends Analysis Report By Drug Class (GLP-1 Receptor Agonists, Dual GIP/GLP-1 Agonists, Triple or Multi-Receptor Agonists, Centrally Acting Sympathomimetics, Peripherally Acting Lipase Inhibitors), By Type (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, E-commerce) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 28, 2026 | Author: Dhanashri B | Format: | Report Code: SR7876DR | Pages: 210
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-obesity Drugs Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. GLP-1 Receptor Agonists
    2. Dual GIP/GLP-1 Agonists
    3. Triple or Multi-Receptor Agonists
    4. Centrally Acting Sympathomimetics
    5. Peripherally Acting Lipase Inhibitors
  2. Anti-obesity Drugs Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Prescription Drugs
    2. OTC Drugs
  3. Anti-obesity Drugs Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. E-commerce
  4. Regional Anti-obesity Drugs Market
    1. North America
      1. North America Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
      2. North America Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Prescription Drugs
        2. OTC Drugs
      3. North America Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. E-commerce
      4. U.S.
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      5. Canada
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
    2. Europe
      1. Europe Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
      2. Europe Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Prescription Drugs
        2. OTC Drugs
      3. Europe Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. E-commerce
      4. U.K.
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      5. Germany
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      6. France
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      7. Spain
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      8. Italy
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      9. Russia
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      10. Nordic
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      11. Benelux
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      12. Rest of Europe
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
    3. APAC
      1. APAC Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
      2. APAC Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Prescription Drugs
        2. OTC Drugs
      3. APAC Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. E-commerce
      4. China
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      5. Korea
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      6. Japan
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      7. India
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      8. Australia
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      9. Taiwan
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      10. South East Asia
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      11. Rest of Asia-Pacific
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
    4. Middle East and Africa
      1. Middle East and Africa Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
      2. Middle East and Africa Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Prescription Drugs
        2. OTC Drugs
      3. Middle East and Africa Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. E-commerce
      4. UAE
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      5. Turkey
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      6. Saudi Arabia
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      7. South Africa
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      8. Egypt
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      9. Nigeria
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      10. Rest of MEA
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
    5. LATAM
      1. LATAM Anti-obesity Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
      2. LATAM Anti-obesity Drugs Market By Type 2022-2034 (USD MILLION/ Units)
        1. Prescription Drugs
        2. OTC Drugs
      3. LATAM Anti-obesity Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. E-commerce
      4. Brazil
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      5. Mexico
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      6. Argentina
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      7. Chile
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      8. Colombia
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
      9. Rest of LATAM
        1. GLP-1 Receptor Agonists
        2. Dual GIP/GLP-1 Agonists
        3. Triple or Multi-Receptor Agonists
        4. Centrally Acting Sympathomimetics
        5. Peripherally Acting Lipase Inhibitors
        6. Prescription Drugs
        7. OTC Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. E-commerce
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.